Jacobs Levy Equity Management, Inc Spero Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$11.65 - $22.07 $1.44 Million - $2.73 Million	-123,688 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$8.96 - $14.12 $561,451 - $884,787	-62,662 Reduced 33.63%	123,688 $1.38 Million
Q2 2020 Aug 17, 2020	BUY	$7.27 - $14.18 $829,906 - $1.62 Million	114,155 Added 158.12%	186,350 $2.52 Million
Q1 2020 May 15, 2020	BUY	$5.27 - $10.41 $138,822 - $274,220	26,342 Added 57.45%	72,195 $583,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $338,554 - $435,182	35,788 Added 355.57%	45,853 $441,000
Q3 2019 Nov 14, 2019	BUY	$9.01 - $12.55 $90,685 - $126,315	10,065 New	10,065 $107,000
Q2 2019 Aug 13, 2019	SELL	$10.25 - $14.36 $391,775 - $548,867	-38,222 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$6.26 - $13.31 $142,615 - $303,228	22,782 Added 147.55%	38,222 $490,000
Q4 2018 Feb 14, 2019	SELL	$5.69 - $11.28 $6,162 - $12,216	-1,083 Reduced 6.55%	15,440 $95,000
Q3 2018 Nov 14, 2018	SELL	$9.69 - $17.79 $166,231 - $305,187	-17,155 Reduced 50.94%	16,523 $174,000
Q2 2018 Aug 14, 2018	BUY	$10.41 - $17.85 $350,587 - $601,152	33,678 New	33,678 $494,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33.3M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.